Rho (D) immune globulin

Kathryn Dzintars, Pharm.D., BCPS, Paul A. Pham, Pharm.D.

INDICATIONS

FDA

  • Suppression of Rh isoimmunization in non-sensitized, Rh o (D)-negative women to reduce likelihood of hemolytic disease in Rh o (D)-positive fetus in present and future pregnancies.
  • Treatment of ITP (including ITP secondary to HIV) in non-splenectomized, Rh o (D)-positive pts.

There's more to see -- the rest of this topic is available only to subscribers.

Last updated: February 26, 2017